Stock Symbol:   

Stoxline Mobile
Home  |  Stock Charts  |  Showcases  |  Stock Ranks  |  Options  |  ETFs  |  Educations  |  Forex Crypto

Panbela Therapeutics, Inc. (PBLA)

0.51   0.022 (4.51%) 03-24 16:00
Open: 0.481 Pre. Close: 0.488
High: 0.53 Low: 0.48
Volume: 488,725 Market Cap: 7(M)

Technical analysis

as of: 2023-03-24 4:28:41 PM
Stoxline posted a BUY today, upgraded from lower rating. Upward movement to be expected.
Target: Six months: 1.25     One year: 1.72
Support: Support1: 0.4    Support2: 0.34
Resistance: Resistance1: 1.07    Resistance2: 1.48
Pivot: 0.63
Moving Average: MA(5): 0.51     MA(20): 0.74
MA(100): 2.88     MA(250): 26.43
MACD: MACD(12,26): -0.3     Signal(9): -0.4
Stochastic oscillator: %K(14,3): 17.3     %D(3): 15.9
RSI: RSI(14): 26.5
52-week: High: 87.59  Low: 0.4
Average Vol(K): 3-Month: 1,905 (K)  10-Days: 943 (K)

Price, moving averages and Bollinger Bands

Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and BEARISH in mid-long term.
[ PBLA ] has closed above bottom band by 22.2%. Bollinger Bands are 78.7% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 124 bars. This is a sign that the market may be about to initiate a new trend.

Stock Price Prediction

Update at 5:00pm EST
If tomorrow: Open lower Open higher
High: 0.53 - 0.53 0.53 - 0.54
Low: 0.47 - 0.48 0.48 - 0.48
Close: 0.51 - 0.51 0.51 - 0.51

Company Description

Panbela Therapeutics, Inc., a clinical-stage biopharmaceutical company, together with its subsidiaries, focuses on developing disruptive therapeutics for the treatment of patients with cancer. The company focuses on diseases of the pancreas, including pancreatitis and pancreatic cancer, as well as neoadjuvant pancreatic cancer, colorectal cancer, ovarian cancer, and other agents in other cancer indications. Its lead product candidate is SBP-101, which is in Phase Ia/Ib clinical trial for the treatment of patients with metastatic pancreatic ductal adenocarcinoma. The company was formerly known as Sun BioPharma, Inc. and changed its name to Panbela Therapeutics, Inc. in December 2020. Panbela Therapeutics, Inc. was incorporated in 2011 and is based in Waconia, Minnesota.

Headline News

Mon, 20 Mar 2023
Breakeven On The Horizon For Panbela Therapeutics, Inc. (NASDAQ:PBLA) - Simply Wall St

Sat, 18 Mar 2023
Panbela Therapeutics, Inc. (NASDAQ:PBLA) Q4 2022 Earnings Call Transcript - Yahoo Finance

Thu, 16 Mar 2023
Panbela Provides Business Update and Reports Q4 and FY 2022 ... - GlobeNewswire

Thu, 16 Mar 2023
Panbela Therapeutics Reports Q4 2022 Financial Results - Best Stocks

Wed, 08 Mar 2023
Panbela to Host Fourth Quarter and Year End 2022 Earnings Conference Call on March 16, 2023 - Yahoo Finance

Thu, 02 Mar 2023
Should You Sell Panbela Therapeutics Inc (PBLA) Stock Thursday Morning? - InvestorsObserver

Financial Analysis

Price to Book Value: Neutral
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.
Price to Earnings: Neutral
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).
Discounted cash flow: Outperform
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.
Return on Assets: Underperform
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.
Return on Equity: Outperform
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.
Debt to Equity: Underperform
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.
Free Technical Analysis Charts

Stock Basics & Statistics

Exchange:  NASDAQ
Sector:  Healthcare
Industry:  Biotechnology
Shares Out. 0 (M)
Shares Float 1 (M)
% Held by Insiders 741500 (%)
% Held by Institutions 6.5 (%)
Shares Short 20 (K)
Shares Short P.Month 0 (K)

Stock Financials

EPS Est Next Qtl 0
EPS Est This Year 0
EPS Est Next Year 0
Book Value (p.s.) 0
Profit Margin (%) 0
Operating Margin (%) 0
Return on Assets (ttm) -92.1
Return on Equity (ttm) -1
Qtrly Rev. Growth 0
Gross Profit (p.s.) 0
Sales Per Share 295.62
EBITDA (p.s.) 0
Qtrly Earnings Growth -0.7
Operating Cash Flow 0 (M)
Levered Free Cash Flow -12 (M)

Stock Valuations

PE Ratio 0
PEG Ratio 0
Price to Book value 0
Price to Sales 0
Price to Cash Flow 0.52

Stock Dividends

Dividend 0
Forward Dividend 417690
Dividend Yield 0%
Dividend Pay Date 2017-11-07
Ex-Dividend Date Invalid DateTime.
Your Ad Here
StockChart iOS
StoxlineLite iOS
StoxlineLite iOS
OptionCalc iOS
StockChart Android
StoxlineLite Android
StoxlinePro Android
OptionCalc Android
(c) 2006-2022 | Contact us           
Data and information is provided for informational purposes only, and is not intended for trading purposes. Neither nor its data provider shall be liable for any errors or delays in the content, or for any actions taken in reliance thereon. By accessing the web site, a user agrees not to redistribute the information found therein.